Wang Jing, Liu Xiaofeng, Li Qun
Department of Gastroenterology, The 960th Hospital of the PLA, Jinan, Shandong, China.
Front Neurosci. 2023 Mar 2;17:1158057. doi: 10.3389/fnins.2023.1158057. eCollection 2023.
The microbiota-gut-brain axis connects the brain and the gut in a bidirectional manner. The organism's homeostasis is disrupted during an ischemic stroke (IS). Cerebral ischemia affects the intestinal flora and microbiota metabolites. Microbiome dysbiosis, on the other hand, exacerbates the severity of IS outcomes by inducing systemic inflammation. Some studies have recently provided novel insights into the pathogenesis, efficacy, prognosis, and treatment-related adverse events of the gut microbiome in IS. In this review, we discussed the view that the gut microbiome is of clinical value in personalized therapeutic regimens for IS. Based on recent non-clinical and clinical studies on stroke, we discussed new therapeutic strategies that might be developed by modulating gut bacterial flora. These strategies include dietary intervention, fecal microbiota transplantation, probiotics, antibiotics, traditional Chinese medication, and gut-derived stem cell transplantation. Although the gut microbiota-targeted intervention is optimistic, some issues need to be addressed before clinical translation. These issues include a deeper understanding of the potential underlying mechanisms, conducting larger longitudinal cohort studies on the gut microbiome and host responses with multiple layers of data, developing standardized protocols for conducting and reporting clinical analyses, and performing a clinical assessment of multiple large-scale IS cohorts. In this review, we presented certain opportunities and challenges that might be considered for developing effective strategies by manipulating the gut microbiome to improve the treatment and prevention of ischemic stroke.
微生物群-肠-脑轴以双向方式连接大脑和肠道。在缺血性中风(IS)期间,机体的稳态会被破坏。脑缺血会影响肠道菌群和微生物群代谢产物。另一方面,微生物群失调会通过引发全身炎症加剧IS的严重程度。最近一些研究为肠道微生物群在IS的发病机制、疗效、预后及治疗相关不良事件方面提供了新的见解。在本综述中,我们探讨了肠道微生物群在IS个性化治疗方案中具有临床价值的观点。基于近期关于中风的非临床和临床研究,我们讨论了通过调节肠道细菌菌群可能开发的新治疗策略。这些策略包括饮食干预、粪便微生物群移植、益生菌、抗生素、中药和肠道来源干细胞移植。尽管针对肠道微生物群的干预前景乐观,但在临床转化之前仍有一些问题需要解决。这些问题包括更深入地了解潜在的机制,对肠道微生物群和宿主反应进行具有多层数据的更大规模纵向队列研究,制定进行和报告临床分析的标准化方案,以及对多个大规模IS队列进行临床评估。在本综述中,我们提出了通过操纵肠道微生物群来制定有效策略以改善缺血性中风的治疗和预防可能需要考虑的某些机遇和挑战。